Hints and tips:
Related Special Reports
..., as well as share their experiences of health conditions....
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...In an interview days before her two-year anniversary as CEO, Sistani described the challenge she faces as less financial than strategic: to pull off a business pivot as profound as those that have convulsed...
...The first three sources are not the exclusive realm of knowledge industries such as tech or pharma....
...Pfizer has agreed to buy US biotech Biohaven Pharmaceuticals for $11.6bn, striking its biggest deal in more than five years as the pharma company bolsters its pipeline of drugs....
...He was previously chief of the Roche diagnostics business, and is now focusing on improving the future of the pharmaceutical division with internal development and deals, after disappointments including...
...MSD’s investment comes as other drugmakers have warned they are being discouraged from doing so....
...The antitrust challenge may force big pharma groups to rethink “pure play” business models. The Lex team is interested in hearing more from readers. Is the FTC right to challenge pharma deals?...
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...“Their business model is contingent on state subsidies,” said Jorge Guajardo, a former Mexican ambassador to China and now a partner at Dentons Global Advisors....
...What that shows is that big companies have shied away from doing mega deals but smaller acquisitions have gone ahead as they probably posed less of a threat....
...US regulators have warned that “rampant consolidation” in the pharmaceuticals industry is pushing up prices for patients as the Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon...
...“We love the Haleon business but it’s not strategic,” said Denton....
...In his first public comments since its employee was arrested in late March on espionage charges, Naoki Okamura said Japan’s second-largest pharmaceutical company by revenue planned to take further steps...
...“It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,” Warren said....
...Finding and assessing prospects in the pharma market takes time, according to Denton, an experienced dealmaker who when working as chief financial officer at pharmacy giant CVS in 2018 oversaw its $68bn...
...The company’s development of new drugs has not advanced as quickly as it forecast....
...For the GSK legal team, this meant recasting itself to support a smaller, more focused pharmaceutical business....
...When acquired, in fairness, Vectura was reshaping its business to become a contract development and manufacturing organisation, using its expertise on behalf of other pharma companies....
...Judges have pushed back on “mass tort” bankruptcies involving 3M and Purdue Pharma....
...” in pharmaceuticals....
...Apply P&G’s trailing multiple and the business could be worth as much as $49bn. That would be a stretch. The US equity capital markets are in a deep freeze....
...Gilead SciencesO: 6; L: 8; I: 7; Total: 21The South Korean legal team at the US-based pharma group increased self-service on legal issues in the rest of the business....
...Doing business with Communist China presents a unique, substantial, pressing risk that warrants dedicated reporting. 2....
...“People were thinking that I’m trying to go into the pharma business [as] window dressing for my tobacco business,” he says. He is accustomed to receiving a frosty reception from scientists....
International Edition